Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit

Rhea-AI Summary

Harpoon Therapeutics (NASDAQ: HARP) announced that CEO Jerry McMahon, Ph.D., will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 10:30 a.m. ET. A live audio webcast will be available on Harpoon's website, with an archived replay following the event.

Harpoon is focused on developing T cell engagers for cancer treatment, utilizing its TriTAC platform. Key pipeline candidates include HPN424, HPN536, HPN217, and HPN328, targeting various cancers. For more details on Harpoon's innovation, visit their website.

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7^th Annual Truist Securities Life Sciences Summit. The event will take place on Wednesday, May 5, 2021 at 10:30 a.m. ET (7:30 a.m. PT).

A live audio webcast of the panel will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com with an archived replay available following the event.

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC^®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Contacts:

Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com

Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com 

FAQ

What is the date and time of Harpoon Therapeutics' fireside chat?

The fireside chat is scheduled for May 5, 2021, at 10:30 a.m. ET.

Who is participating in the Truist Securities Life Sciences Summit for Harpoon Therapeutics?

Jerry McMahon, Ph.D., President and CEO of Harpoon Therapeutics, will participate.

Where can I listen to the Harpoon Therapeutics fireside chat?

A live audio webcast will be available on the Investors section of Harpoon Therapeutics' website.

What is the focus of Harpoon Therapeutics' clinical pipeline?

Harpoon Therapeutics focuses on immunotherapy, specifically T cell engagers for treating various cancers.

What are some key candidates in Harpoon Therapeutics' pipeline?

Key pipeline candidates include HPN424 for prostate cancer, HPN536 for mesothelin-expressing cancers, HPN217 for multiple myeloma, and HPN328 for small cell lung cancer.